1830 East Monument Street, Suite 333, Baltimore, MD 21287, USA.
Curr Infect Dis Rep. 2006 Nov;8(6):497-504. doi: 10.1007/s11908-006-0025-5.
In recent years, substantial progress has been made in our understanding of the pathogenesis, risk factors, and treatment of glucose and lipid abnormalities in HIV-infected patients. Newer antiretrovirals, such as abacavir and tenofovir in the nucleoside reverse transcriptase class and atazanavir in the protease inhibitor class, have been shown to improve metabolic profiles compared to other medications. In addition, new information regarding the efficacy of glucose and lipid-lowering medications in HIV-infected patients has become available. It has also been demonstrated that aggressive risk factor modification can reduce the burden of cardiovascular disease in this population. This article reviews these recent advances in order to help providers respond to these important clinical challenges.
近年来，我们对 HIV 感染患者的血糖和血脂异常的发病机制、危险因素和治疗有了更深入的了解。新型抗逆转录病毒药物，如核苷逆转录酶抑制剂类的阿巴卡韦和替诺福韦，以及蛋白酶抑制剂类的阿扎那韦，与其他药物相比，可改善代谢指标。此外，有关 HIV 感染患者降血糖和血脂药物疗效的新信息也已面世。此外，研究还表明，积极的危险因素修正可以降低该人群的心血管疾病负担。本文综述了这些新进展，旨在帮助临床医生应对这些重要的临床挑战。
